Despite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
|
|
- Gary Johnson
- 5 years ago
- Views:
Transcription
1 ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for almotriptan. Methods: Almotriptan has been evaluated in more than 3500 acute migraine patients in phase 2 and 3 double-blind, randomized trials and in 1500 patients in long-term open-label trials. Results: Controlled clinical trials show that almotriptan 12.5 mg is significantly more effective than placebo. These results are observed across different endpoints examined, including pain relief at 2 hours, pain-free outcome at 2 hours, recurrence rate, use of escape medication, and sustained pain-free outcome. The onset of pain relief is observed as early as 30 minutes after administration. Results from a multiple-attack study show that almotriptan maintains a consistency of response across 3 attacks, and results from long-term studies confirm that patients continue to respond to almotriptan for up to 1 year. Results from 2 comparative studies show that almotriptan 12.5 mg has comparable efficacy to sumatriptan 50 or 100 mg, but almotriptan has a superior tolerability profile. Early use of almotriptan results in a higher proportion of patients achieving pain relief or complete freedom from pain. Conclusions: Because almotriptan has a tolerability profile comparable to that of placebo, it may be more acceptable for early administration. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than recorded with sumatriptan. In addition, almotriptan has a low incidence of chest symptoms, an adverse event associated with triptan use. Because of its comparable efficacy and superior tolerability profile, almotriptan offers a potential improvement over existing triptans for the treatment of acute migraine. (Am J Manag Care 2002;8:S74 S79) Despite the widespread use of triptans for acute migraine treatment and a favorable response by the majority of patients, many patients continue to report unmet needs for acute migraine. 1 When surveyed about their treatment expectations for acute migraine, patients report a need for therapy that is rapidly effective, relieves pain completely, has a low recurrence rate, and is well tolerated. 1 Although triptans offer many of these attributes, a recent survey from the National Headache Foundation indicated that patients remain dissatisfied (see article by Gallagher and Cutrer in this supplement). Almotriptan is the most recent 5- HT 1B/1D receptor agonist marketed for the treatment of acute migraine. Preclinical studies indicate that almotriptan is highly selective for meningeal arteries, with a lower affinity for cardiac, pulmonary, and other peripheral arterial beds. 2 Almotriptan has been evaluated in more than 3500 acute migraine patients in phase 2 and 3 double-blind, randomized trials and in an additional 1500 patients in long-term openlabel trials. Results from these trials indicate that almotriptan 12.5 mg is effective for the treatment of acute migraine, with a rapid onset of activity and a tolerability profile comparable to placebo. This article summarizes the preclinical and clinical data for almotriptan. Pharmacology Similar to other triptans, almotriptan exerts potent vasoconstrictor activity on 5- HT 1B/1D receptor sites in meningeal arteries. 3 According to studies in isolated human arteries, almotriptan was at least as potent as sumatriptan in meningeal arteries but significantly less potent than sumatriptan in coronary and pulmonary arteries. 2 S74 THE AMERICAN JOURNAL OF MANAGED CARE FEBRUARY 2002
2 Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Almotriptan is well absorbed after oral administration, with an oral bioavailability of 70%. 4 The absorption of almotriptan is not affected by food, age, gender, or administration during or after a migraine attack. 5-7 Although peak plasma levels of almotriptan occur at 2.5 hours, the onset of pain relief has been observed within 30 minutes of administration. 8 Almotriptan is eliminated by both renal elimination and hepatic metabolism. 9 Approximately 55% is excreted unchanged via urine and stool and the remaining 45% is metabolized by monoamine oxidase-a and the cytochrome P-450 system. The elimination half-life of almotriptan is 3 to 4 hours. 4 The drug-interaction potential of almotriptan coadministered with fluoxetine, verapamil, propranolol, and moclobemide, a monoamine oxidase-a inhibitor, has been evaluated in human volunteers No clinically relevant change in the pharmacokinetic profile of almotriptan was noted, and no dosage modification is recommended when almotriptan is taken with other drugs. Almotriptan has been evaluated in a number of phase 1 studies in healthy volunteers. 6,7,9,14 Almotriptan was found to be well tolerated in elderly patients and in those with varying degrees of renal impairment. 6,7 Further, no clinically relevant adverse effects on the cardiovascular system were observed at doses up to 200 mg in either healthy volunteers or patients with acute migraine. 9,14,15 Clinical Efficacy The efficacy of almotriptan has been evaluated in 4 double-blind, randomized trials of patients satisfying International Headache Society (IHS) criteria for moderate-to-severe acute migraine (Table 1). 8,16-18 Three trials were placebo controlled, including 1 trial that had a sumatriptan 100-mg comparator group 17 and 1 trial that assessed the response across 3 successive episodes of acute migraine. 18 A fourth trial compared almotriptan 12.5 mg and sumatriptan 50 mg. 16 In a dose-finding study, patients with moderate-to-severe acute migraine were randomized to placebo or oral almotriptan 2, 6.25, 12.5, or 25 mg. 8 Of 742 patients evaluated, pain relief at 2 hours was 32.5% with placebo and 30%, 56.3%, 58.5%, and 66.5% with almotriptan 2-, 6.25-, 12.5-, and 25-mg doses, respectively (P <.05 for 6.25, 12.5, and 25 mg versus placebo). The onset of pain relief was observed at 30 minutes with almotriptan 12.5 mg. The percentage of patients who were completely pain free at 2 hours was 37.8% and 45.3% in the 12.5 and 25 mg almotriptan groups, respectively, compared with 11.3% in the placebo group (Figure 1). The incidence of adverse events with the almotriptan 2-, 6.25-, and 12.5-mg groups was comparable to that with the placebo group. Almotriptan 12.5 mg had the most favorable ratio between efficacy and tolerability. The efficacy and tolerability of single doses of almotriptan 6.25 and 12.5 mg were evaluated in 722 patients who were treated for 3 consecutive moderate-tosevere migraine attacks. 18 Significant pain relief was noted as early as 1 hour with almotriptan. Across all migraine attacks, pain relief at 2 hours was achieved in 60% of patients with almotriptan 6.25 mg, 70% with almotriptan 12.5 mg, and 38% with placebo (P <.001). Pain relief at 2 hours Table 1. Summary of Double-Blind, Randomized Trials of Almotriptan for the Treatment of Moderate-to-Severe Acute Migraine Reference Treatment Regimens Number of Patients Dahlöf et al, Placebo 80 Almotriptan 2 mg 170 Almotriptan 6.25 mg 167 Almotriptan 12.5 mg 164 Almotriptan 25 mg 161 Dowson, Placebo 99 Almotriptan 12.5 mg 183 Almotriptan 25 mg 191 Sumatriptan 100 mg 194 Pascual et al, Placebo 131 Almotriptan 6.25 mg 287 Almotriptan 12.5 mg 304 Spierings et al, Almotriptan 12.5 mg 591 Sumatriptan 50 mg 582 VOL. 8, NO. 3, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S75
3 REPORTS was achieved in 75% of patie nts for 2 of 3 attacks and in 49% of patients for 3 of 3 attacks. Across all attacks, 38.8% of patients with almotriptan 12.5 mg and 29.9% with almotriptan 6.25 mg were pain free at 2 hours compared with 15.5% with placebo (P <.001; Figure 2). Recurrence Figure 1. Percentage of Patients Pain Free After Treatment With Almotriptan or Placebo Patients (%) Placebo Almotriptan 2 mg Almotriptan 6.25 mg Almotriptan 12.5 mg Almotriptan 25 mg Assessment Time (Hours) P <.0001, Cochran-Mantel-Haenszel test for all doses of almotriptan at 1, 1.5, and 2 hours. Figure 2. Percentage of Patients Pain Free at 2 Hours Across 3 Consecutive Migraine Attacks With Almotriptan and Placebo P <.001 for comparisons of almotriptan 6.25 and 12.5 mg versus placebo. Source: Reference 18. rates were 28.7% and 30.1% with almotriptan 6.25 and 12.5 mg, respectively, and 23.3% with placebo. The incidence of treatment-related adverse events and discontinuation for adverse events with almotriptan was comparable to that of placebo. Thus, almotriptan 12.5 mg demonstrated a consistent response across multiple migraine attacks and offered the optimal balance of efficacy and tolerability. Almotriptan 12.5 and 25 mg and sumatriptan 100 mg were compared in a placebo-controlled trial of 668 patients. 17 At 2 hours, pain relief was recorded in 58% to 64% of patients in active treatment groups compared with 42% of patients on placebo (Figure 3). Freedom from pain at 2 hours was noted in 28%, 35%, and 34% of patients in the almotriptan 12.5-, 25-, and sumatriptan 100-mg groups, respectively, and in 15% of patients in the placebo group. The recurrence rate was 18.0% and 15.4% with almotriptan 12.5 and 25 mg, respectively, 24.6% with sumatriptan, and 19.5% with placebo. The incidence of any adverse event was comparable with almotriptan 12.5 mg (8.7%) and placebo (6.1%). Spierings et al 16 reported the results from a comparison of almotriptan 12.5 mg and sumatriptan 50 mg in 1173 patients. At 2 hours, pain relief was recorded in 58.0% of almotriptan-treated and 57.3% of sumatriptan-treated patients. No significant differences among groups were observed in recurrence rate (27.4% almotriptan and 24.0% sumatriptan), use of rescue medication, or incidence of migraine-associated symptoms. Significantly more patients treated with sumatriptan were pain free at 2 hours (24.6% versus 17.9%, P =.005). Whereas the incidence of all treatment-related adverse events was 15.5% with sumatriptan and 9.1% with almotriptan (P =.001), the incidence of chest pain was 2.2% with sumatriptan and 0.3% with almotriptan (P =.004). Thus, almotriptan and sumatriptan exhibited comparable efficacy, but almotriptan was better tolerated (Figure 4). Sustained pain-free outcome has been identified by the IHS as more relevant than pain relief to patient needs. 19 S76 THE AMERICAN JOURNAL OF MANAGED CARE FEBRUARY 2002
4 Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Sustained pain-free outcome is defined as a decrease in pain severity from moderate or severe at baseline to no pain at 2 hours postdose and without relapse or the use of escape medication between 2 and 24 hours. A pooled analysis of 3 randomized, double-blind, placebo-controlled trials of almotriptan was conducted to examine the sustained pain-free outcome. 20 Among 1791 patients, the proportion achieving a sustained pain-free state was significantly (P <.05) higher in the almotriptan 6.25 mg (21.7% to 22.5%) and 12.5 mg (24.6% to 27.6%) groups than in the placebo group (7.5% to 12.1%). The proportion of patients achieving a sustained pain-free state was comparable between the almotriptan mg (24.6%) and sumatriptan 100-mg (28.5%) groups. Thus, almotriptan 12.5 mg was significantly better than placebo and comparable to sumatriptan 100 mg for achieving a sustained pain-free state. Two open-label, long-term trials have been completed with almotriptan. 21,22 One study, which included 762 patients, evaluated 13,751 migraine attacks of any intensity treated with almotriptan 12.5 mg over a 1-year period. 21 Pain relief and pain-free rates at 2 hours were 84% and 58% of attacks, respectively. Treatment-related adverse events were reported in 29% of patients, but most were of mild intensity and were transient. A post hoc analysis from this study was performed in 118 patients who had been treated for at least 3 attacks of mild intensity and 3 of moderate or severe intensity (J. Pascual, unpublished data, 2001). At 1 hour, 47% of mild attacks and 14% of moderate-tosevere attacks were pain free (P <.001). In addition, lower recurrence rates and use of escape medication were observed with mild attacks. This study suggests that early intervention with almotriptan when migraine pain is of mild, rather than moderate or severe, intensity results in an improved response. The second study was a 6-month openlabel trial of almotriptan 12.5 mg. 22 Among 582 patients, the most frequent drug-related adverse events were nausea (3.1%) and dizziness (2.4%). Adverse events led to discontinuation of treatment in 36 (6.2%) patients. Drug-related chest pain was reported in 9 (1.5%) patients. No serious drug-related adverse events were reported and no deaths occurred. Pain relief at 2 hours was reported for 76% of all migraine attacks, and 49% were pain free at 2 hours after the first drug dose. Figure 3. Percentage of Patients With Pain Relief or Pain Free at 2 Hours All active groups significantly (P <.05) different from placebo. Source: Reference 17. Figure 4. Results From Efficacy and Tolerability Assessments of Sumatriptan 50 mg and Almotriptan 12.5 mg AE = adverse event. Source: Reference 16. VOL. 8, NO. 3, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S77
5 REPORTS Table 2. Incidence of Adverse Events Occurring in at Least 1% of Patients in Placebo-Controlled Trials of Almotriptan ALM ALM ALM SMT Placebo 6.25 mg 12.5 mg 25 mg 50 mg (N = 386) (N = 527) (N = 1313) (N = 387) (N = 582) Adverse Event n (%) n (%) n (%) n (%) n (%) Body Asthenia 3 (0.8) 4 (0.8) 9 (0.7) 10 (2.6) 2 (0.3) Chest pain 1 (0.3) 1 (0.2) 3 (0.2) 5 (1.3) 13 (2.2) Headache 4 (1.0) 4 (0.8) 15 (1.1) 3 (0.8) 9 (1.5) Localized pain 1 (0.3) 2 (0.4) 8 (0.6) 5 (1.3) 3 (0.5) Cardiovascular Palpitation 2 (0.5) 4 (0.8) 3 (0.2) 7 (1.8) 0 Vasodilation 0 2 (0.4) 9 (0.7) 4 (1.0) 8 (1.4) Digestive Dry mouth 2 (0.5) 6 (1.1) 9 (0.7) 4 (1.0) 4 (0.7) Nausea 5 (1.3) 4 (0.8) 26 (2.0) 6 (1.6) 20 (3.4) Nervous Dizziness 7 (1.8) 7 (1.3) 22 (1.7) 8 (2.1) 10 (1.7) Paresthesia 2 (0.5) 6 (1.1) 16 (1.2) 4 (1.0) 5 (0.9) Somnolence 4 (1.0) 3 (0.6) 17 (1.3) 9 (2.3) 11 (1.9) ALM = almotriptan; SMT = sumatriptan. Source: Reference 23. Tolerability Overall, almotriptan demonstrates a tolerability profile comparable to placebo. A pooled analysis assessed the safety and tolerability of almotriptan from phase 1, 2, and 3 studies. 15 Phase 2 and 3 studies included more than 2500 patients who were treated for over 15,000 migraine attacks. Adverse events occurring in at least 1% of patients treated with almotriptan are listed in Table Most adverse events were of mild-to-moderate intensity. The incidence of adverse events with almotriptan 12.5 mg and placebo was comparable. In both comparative trials of almotriptan and sumatriptan, the incidence of treatment-related adverse events was significantly higher with sumatriptan. 16,17 In phase 3 trials, the incidence of chest symptoms with almotriptan was 0.2%. In phase 1 trials in healthy volunteers, no significant cardiovascular safety issues were recorded, including electrocardiographic abnormalities or clinically relevant changes in blood pressure. 15 Conclusion Based on results from controlled clinical trials in more than 3000 patients, almotriptan 12.5 mg is significantly more effective than placebo. These results are observed across different endpoints examined, including pain relief at 2 hours, pain free at 2 hours, recurrence rate, use of escape medication, and sustained painfree outcome. The onset of pain relief is observed as early as 30 minutes after administration. Results from a multipleattack study show that almotriptan maintains a consistency of response across 3 attacks, and results from long-term studies confirm that patients continue to respond to almotriptan for up to 1 year. Results from 2 comparative studies show that almotriptan 12.5 mg has comparable efficacy to sumatriptan 50 or 100 mg, but almotriptan has a superior tolerability profile. Early use of almotriptan results in a higher proportion of patients achieving pain relief or complete freedom from pain. The incidence of treatment-related adverse events with almotriptan is comparable to that of placebo and significantly lower than that recorded with sumatriptan. In addition, almotriptan has a low incidence of chest symptoms. Because of its comparable efficacy and superior tolerability profile, almotriptan offers a potential improvement over existing triptans for the treatment of acute migraine.... REFERENCES Lipton RB, Stewart WF. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999;39(suppl 2):S20- S Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001;21: Bou J, Domenech T, Puig J, et al. Pharmacological characterization of almotriptan: An indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000;410: Fernandez FJ, Jansat JM, Cabarrocas X, Costa J, Salva P. Absolute bioavailability of oral and subcutaneous almotriptan [abstract]. Cephalalgia 1999;19:363. S78 THE AMERICAN JOURNAL OF MANAGED CARE FEBRUARY 2002
6 Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability 5. Garcia E, Cabarrocas X, Jansat JM. A clinical trial to determine the lack of food interaction on the bioavailability of almotriptan, a new 5HT1B/1D agonist, in healthy volunteers [abstract]. Headache 1998;38: Cabarrocas X, Jansat JM, Ferrer P, Luria X. Pharmacokinetics of oral almotriptan during and outside a migraine attack [abstract]. Cephalalgia 1999;19: Cabarrocas X, Warrington SJ, Jansat JM, Zayas JM, Boyce M, Ferrer P. Pharmacokinetics and tolerability of oral almotriptan in the elderly [abstract]. Cephalalgia 1999;19: Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A, for the Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001;57: Cabarrocas X, Salva M. Pharmacokinetic and metabolic data on almotriptan, a new antimigraine drug [abstract]. Cephalalgia 1997;17: Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Effect of MAO-A inhibition on the pharmacokinetics of a novel antimigraine agent, almotriptan, in humans. Paper presented at: Annual Meeting of the American Academy of Neurology; April 17-24,1999; Toronto, Ontario. 11. Fleishaker JC, Sisson TA, Carel BH, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000;67: Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001;41: Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001;21: Boyce M, Dunn K, Warrington S. Hemodynamic and electrocardiographic effects of almotriptan in healthy volunteers. J Cardiovasc Pharmacol 2001;37: Dodick DW. Oral almotriptan in the treatment of migraine: Safety and tolerability. Headache 2001; 41: Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ. Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: A double-blind, randomized, parallelgroup, optimum-dose comparison. Arch Neurol 2001;58: Dowson A. Almotriptan is an effective and welltolerated treatment for migraine pain: Results of a randomised, double-blind, placebo-controlled clinical trial. Cephalalgia In press. 18. Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: Results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000;20: International Headache Society. Guidelines for controlled trials of drugs in migraine: Second edition. International Headache Society Clinical Trials Subcommittee. Cephalalgia 2000;20: Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: Results from 3 controlled clinical trials. Headache In press. 21. Pascual J, Falk R, Docekal R, et al. Tolerability and efficacy of almotriptan in the long-term treatment of migraine. Eur Neurol 2001;45: Mathew N. A long-term open-label study of oral almotriptan 12.5 mg for the treatment of acute migraine attacks. Headache In press. 23. Swidan S. Safety and tolerability of almotriptan for the treatment of acute migraine attacks: Pooled analysis of clinical trials. Paper presented at: IHC The 10th Congress of the International Headache Society; June 29-July 2, 2001; New York, NY. VOL. 8, NO. 3, SUP. THE AMERICAN JOURNAL OF MANAGED CARE S79
Value of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
J Headache Pain (2006) 7:27 33 DOI 10.1007/s10194-006-0266-6 ORIGINAL Julio Pascual Hans-Christoph Diener Hélène Massiou Value of postmarketing surveillance studies in achieving a complete picture of antimigraine
More information...SELECTED ABSTRACTS...
The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind
More informationZolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice
J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred
More informationEvaluating the triptans
The American Journal of Medicine (2005) Vol 118, Suppl 1, 28S 35S Evaluating the triptans Ninan T. Mathew, MD, a Elizabeth W. Loder, MD b a From the Houston Headache Clinic, and Department of Neurology,
More informationTreatment satisfaction with zolmitriptan nasal spray for migraine in a real life setting: results from phase two of the REALIZE study
J Headache Pain (2005) 6:405 411 DOI 10.1007/s10194-005-0237-3 ORIGINAL Marek Gawel Jürgen Aschoff Arne May Bruce R. Charlesworth on behalf of the REALIZE Study Group Treatment satisfaction with zolmitriptan
More informationA new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results
J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio
More informationANTIMIGRAINE MEDICINES
1 07.00.00.00 - ANTIMIGRAINE MEDICINES 1. Summary statement For acute migraine therapy the following new medicine is proposed: Sumatriptan 50 mg. 2. 3. Global Campaign to Reduce the Burden of Headache
More informationMigraineurs have specific preferences with regard to migraine therapy. In surveys,
Patient Treatment Preferences and the 5-HT 1B/1D Agonists Robert E. Ryan, Jr, MD REVIEW ARTICLE Migraineurs have specific preferences with regard to migraine therapy. In surveys, they consistently cite
More informationMigraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options
... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options R. Michael Gallagher, DO; and F. Michael Cutrer, MD Abstract Objective: The safety and tolerability of medications used to treat
More informationDrug Class Review on Triptans
Drug Class Review on UPDATED FINAL REPORT #1 December 2003 Mark Helfand, MD, MPH Kim Peterson, MS Oregon Evidence-based Practice Center Oregon Health & Science University Table of Contents Introduction
More informationLasmiditan (200 mg and 100 mg) Compared to Placebo for Acute Treatment of Migraine
(200 mg and 100 mg) Compared to for Acute Treatment of Migraine Bernice Kuca, M.S. 1 ; Linda A. Wietecha, B.S.N., M.S. 2 ; Paul H. Berg, M.S. 2 ; Sheena K. Aurora, M.D. 2 1 CoLucid Pharmaceuticals, Inc.,
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationMEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache
MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended
More informationSetting The setting of the study was primary care. The economic study was conducted in the USA.
A comparison of the cost-effectiveness of almotriptan and sumatriptan in the treatment of acute migraine using a composite efficacy/tolerability end point Williams P, Reeder C E Record Status This is a
More informationM0BCore Safety Profile. Pharmaceutical form(s)/strength: ordispersible tablet SE/H/PSUR/0022/002 Date of FAR:
M0BCore Safety Profile Active substance: Zolmitriptan Pharmaceutical form(s)/strength: ordispersible tablet P-RMS: SE/H/PSUR/0022/002 Date of FAR: 15.03.2014 4.3 Contraindications Zolmitriptan is contraindicated
More informationDrug Class Review on the Triptans
Drug Class Review on the Final Report March 7, 2003 Expires October 31, 2003 Mark Helfand, MD, MPH Kim Peterson, MS Produced by Oregon Health & Science University 3181 SW Sam Jackson Park Road Mailcode:
More informationMigraine: Developing Drugs for Acute Treatment Guidance for Industry
Migraine: Developing Drugs for Acute Treatment Guidance for Industry U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) February 2018
More informationThe use of combination therapies in the acute management of migraine
REVIEW The use of combination therapies in the acute management of migraine Abouch Valenty Krymchantowski Headache Center of Rio, Rio de Janeiro, Brazil; Outpatient Headache Unit of the Instituto de Neurologia
More informationAn Economic Evaluation of Triptan Products for Migraine
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR86647655Original ArticleEconomic Evaluation of TriptansPerfetto et al. Volume 8 Number 6 2005 VALUE IN HEALTH An Economic Evaluation
More informationTriptans: Nonresponse, Recurrence, and Serious AEs for Many Patients
Efficacy, Safety, and Tolerability of Rimegepant 75 mg, an Oral CGRP Receptor Antagonist, for the Acute Treatment of Migraine: Results from a Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial,
More informationmedications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan
J Headache Pain (2007) 8:13 18 DOI 10.1007/s10194-007-0354-7 ORIGINAL Seymour Diamond Fred G. Freitag Alexander Feoktistov George Nissan Sumatriptan 6 mg subcutaneous as an effective migraine treatment
More informationRizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial
J Headache Pain (2007) 8:175 179 DOI 10.1007/s10194-007-0386-7 ORIGINAL Usha Kant Misra Jayantee Kalita Rama Kant Yadav Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial Received:
More informationDrug Class Review on Triptans
Drug Class Review on Triptans Final Report Update 3 November 2005 Original Report Date: March 2003 Update 1 Report Date: December 2003 Update 2 Report Date: September 2004 A literature scan of this topic
More informationZOMIG 2.5 mg Tablet ASTRAZENECA
10-14 ZOMIG 2.5 mg Tablet ASTRAZENECA zolmitriptan TradeMark Presentation Zomig is presented as tablets for oral administration containing 2.5 mg of zolmitriptan. Indication Zomig is indicated for the
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationNew Zealand Data Sheet
Arrow - Sumatriptan Sumatriptan Injection 6mg/0.5mL Presentation New Zealand Data Sheet ARROW SUMATRIPTAN Injection 6mg/0.5mL is a clear, colourless to pale yellow solution in a prefilled syringe. Uses
More informationEletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study
Eletriptan vs sumatriptan: A double-blind, placebo-controlled, multiple migraine attack study G. Sandrini, M. Färkkilä, G. Burgess, et al. Neurology 2002;59;1210-1217 DOI 10.1212/WNL.59.8.1210 This information
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationZolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose response study
is effective and well tolerated in Japanese patients with migraine: a dose response study F Sakai 1, M Iwata 2, K Tashiro 3, Y Itoyama 4, S Tsuji 5, Y Fukuuchi 6, G Sobue 7, K Nakashima 8 & M Morimatsu
More informationRichard B. Lipton, 1 Joel Saper, 2 Messoud Ashina, 3 David Biondi, 4 Suman Bhattacharya, 4 Joe Hirman, 5 Barbara Schaeffler, 4 Roger Cady 4
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PRevention Of Migraine via
More informationSummary of Product Characteristics
Summary of Product Characteristics 1. Name of the Medicinal Product Sumatriptan Merck 50 mg film-coated tablet Sumatriptan Merck 100 mg film-coated tablet 2. Qualitative and Quantitative Composition Each
More informationNARAMIG QUALITATIVE AND QUANTITATIVE COMPOSITION
NARAMIG Naratriptan QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets containing 2.5 mg of naratriptan as naratriptan hydrochloride. PHARMACEUTICAL FORM Film coated tablets. CLINICAL PARTICULARS Indications
More informationPatients preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine
J Headache Pain (2005) 6:112 120 DOI 10.1007/s10194-005-0164-3 REVIEW Andrew J. Dowson Stewart J. Tepper Carl Dahlöf Patients preference for triptans and other medications as a tool for assessing the efficacy
More informationORIGINAL CONTRIBUTION. Oral Almotriptan vs Oral Sumatriptan in the Abortive Treatment of Migraine
ORIGINAL CONTRIBUTION Oral Almotriptan vs Oral Sumatriptan in the Abortive Treatment of Migraine A Double-blind, Randomized, Parallel-Group, Optimum-Dose Comparison Egilius L. H. Spierings, MD, PhD; Baltazar
More informationEarly treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan
Blackwell Science, LtdOxford, UKCHACephalalgia1468-2982Blackwell Science, 20042411925933Original ArticleEarly treatment of migraine with sumatriptanj Scholpp et al. Early treatment of a migraine attack
More informationThe recommended dose of Imigran Suppositories for the acute treatment of a migraine attack is one 25mg suppository administered rectally.
1. NAME OF THE MEDICINAL PRODUCT Imigran 25 mg Suppository. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Imigran 25 mg Suppository: contains 25 mg sumatriptan For a full list of excipients, see section
More informationRizatriptan in the treatment of migraine
EXPERT OPINION Rizatriptan in the treatment of migraine Miguel JA Láinez Department of Neurology, University Clinic Hospital, University of Valencia, Valencia, Spain Correspondence: Miguel JA Láinez Department
More informationEmilio Sternieri Anna Ferrari Arrigo F.G. Cicero
J Headache Pain (2003) 4:13 17 Springer-Verlag 2003 REVIEW Emilio Sternieri Anna Ferrari Arrigo F.G. Cicero Clinical considerations preliminary to application of the Italian Society for the Study of Headache
More informationAcute migr REVIEW 6 PRACTICAL NEUROLOGY
6 PRACTICAL NEUROLOGY REVIEW Pract Neurol: first published as 10.1111/j.1474-7766.2004.03-205.x on 1 February 2004. Downloaded from http://pn.bmj.com/ Acute migr on 15 July 2018 by guest. Protected by
More informationIntroduction. Keywords: ergotamine, migraine, peripheral arteries, rizatriptan
The effect of rizatriptan, ergotamine, and their combination on human peripheral arteries: a double-blind, placebo-controlled, crossover study in normal subjects Peer Tfelt-Hansen, 1 Kaj Seidelin, 1 Michael
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationPRODUCT INFORMATION. SUDAFED Sinus 12 Hour Relief Tablets
PRODUCT INFORMATION SUDAFED Sinus 12 Hour Relief Tablets NAME OF THE MEDICINE Pseudoephedrine Hydrochloride CAS 2 Registry Number: 345-78-8 DESCRIPTION SUDAFED Sinus 12 Hour Relief prolonged-release tablets
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Sumatriptan 100mg film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film coated tablet contains 100mg sumatriptan (as
More informationMigraine much more than just a headache
Migraine much more than just a headache Session hosted by Teva UK Limited PUU4 11:15 12:15 UK/NHSS/18/0021b Date of Preparation: August 2018 The views expressed in this presentation are those of the speaker
More information1/25/2018 ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Disclosures: Objectives: Headache Division
ARE CGRP ANTAGONISTS ANY BETTER THAN CURRENT EVIDENCE BASED TREATMENTS? Lawrence C Newman, MD, FAHS, FAAN Clinical Professor of Neurology Disclosures: Advisory Board: Alder, Allergan, Amgen, Lilly, Supernus,
More informationTopiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders
J Headache Pain (2012) 13:53 59 DOI 10.1007/s10194-011-0395-4 ORIGINAL Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders Abouch Valenty Krymchantowski
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Description Sumatriptan
More informationSeeking the best care for acute migraine
J Headache Pain (2002) 3:1 5 Springer-Verlag 2002 EDITORIAL Marcello Fanciullacci Seeking the best care for acute migraine M. Fanciullacci ( ) Headache Center, Department of Internal Medicine, University
More informationGuidance for Industry Migraine: Developing Drugs for Acute Treatment
Guidance for Industry Migraine: Developing Drugs for Acute Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationDrug Class Review Triptans
Drug Class Review Triptans April 2013 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationWhat is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary
What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More information2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 PRODUCT NAME TROPISETRON-AFT tropisetron hydrochloride (equivalent to 2 mg or 5 mg tropisetron) per ampoule. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 1 mg of tropisetron 1 2 ml ampoule
More informationMAXALT Merck Sharp & Dhome
MAXALT Merck Sharp & Dhome 1. NAME OF THE MEDICINAL PRODUCT MAXALT * 5 mg oral lyophilisates MAXALT 10 mg oral lyophilisates 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each oral lyophilisate contains
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationSYNOPSIS 2/198 CSR_BDY-EFC5825-EN-E02. Name of company: TABULAR FORMAT (For National Authority Use only)
SYNOPSIS Title of the study: A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose (rimonabant 20 mg) multicenter study of long-term glycemic control with rimonabant in treatment-naïve
More informationMaxalt. Maxalt / Maxalt-MLT (rizatriptan) Description. Section: Prescription Drugs Effective Date: April 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Maxalt Page: 1 of 5 Last Review Date: March 18, 2016 Maxalt Description Maxalt / Maxalt-MLT (rizatriptan)
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Triptans: almotriptan, Amerge, Axert, Frova,
More informationLACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION
LACIPIL lacidipine QUALITATIVE AND QUANTITATIVE COMPOSITION Lacidipine, 2 mg - round shaped white engraved on one face. Lacidipine, 4 mg - oval white with break line on both faces. Lacidipine, 6 mg - oval
More informationDrug Review Rozerem (ramelteon)
Drug Review Rozerem (ramelteon) Introduction 1 Ramelteon is a melatonin receptor agonist with affinity for MT 1 and MT 2 and selectivity over the MT 3 receptor. The activity at the MT 1 and MT 2 receptors
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg NL/H/PSUR/0002/001 Date of FAR:
Core Safety Profile Active substance: Rizatriptan Pharmaceutical form(s)/strength: Tablets and Oral lyophilisates (wafers) 5 and 10 mg P RMS: NL/H/PSUR/0002/001 Date of FAR: 23.05.2011 4.3 Contraindications
More informationONZETRA XSAIL (sumatriptan) nasal powder
ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationISPUB.COM. C Suthisisang, N Poolsup, N Suksomboon INTRODUCTION
ISPUB.COM The Internet Journal of Pain, Symptom Control and Palliative Care Volume 8 Number 2 Efficacy And Safety Of Sumatriptan Plus Naproxen Sodium In The Acute Treatment Of Migraine: Systematic Review
More informationDOSAGE FORMS AND STRENGTHS Tablets: 6.25 mg and 12.5 mg (3)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ALMOTRIPTAN TABLETS safely and effectively. See full prescribing information for ALMOTRIPTAN TABLETS.
More informationVenlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study
Clinical Neurology and Neurosurgery 107 (2004) 44 48 Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study Serpil Bulut a,, M. Said Berilgen
More informationNasal Spray, solution. Clear pale yellow to dark yellow liquid, in glass vials in a single dose nasal spray device.
1. NAME OF THE MEDICINAL PRODUCT Imigran 10 mg Nasal Spray. Imigran 20 mg Nasal Spray. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Imigran 10 mg Nasal Spray: Unit dose spray device for intranasal administration.
More informationSumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.11 Subject: Sumatriptan Injection Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Injection
More informationTHE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE
Rapoport Ch 05.qxd 10/15/08 1:06 PM Page 25 CHAPTER 5 THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE ALLAN PURDY, MD, FRCPC FRED SHEFTELL, MD ALAN RAPOPORT, MD STEWART J. TEPPER, MD Case History
More informationMigraine headache incurs estimated. The Cost of Migraine and Its Treatment REPORTS. Lawrence D. Goldberg, MD, MBA
REPORTS The Cost of Migraine and Its Treatment Lawrence D. Goldberg, MD, MBA Abstract Migraine headache incurs estimated annual costs totaling as much as $17 billion in the United States. Most of the direct
More informationNEW ZEALAND DATA SHEET
NEW ZEALAND DATA SHEET 1. PRODUCT NAME IMIGRAN sumatriptan succinate 50 mg and 100 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 50 mg or 100 mg of sumatriptan base, as the
More informationNEW ZEALAND DATA SHEET
Naramig Tablets Naratriptan 2.5mg NEW ZEALAND DATA SHEET Presentation Green film coated, D shaped, biconvex tablets engraved GX CE5 on one face. Each tablet contains 2.5mg of naratriptan as naratriptan
More informationPreventive Effect of Greater Occipital Nerve Block on Severity and Frequency of Migraine Headache
Global Journal of Health Science; Vol. 6, No. 6; 2014 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Preventive Effect of Greater Occipital Nerve Block on Severity
More informationUNIVERSA MEDICINA. The role of triptans in the management of migraine
UNIVERSA MEDICINA January-April, 2009 Vol.28 - No.1 The role of triptans in the management of migraine Meiyanti* ABSTRACT *Department of Pharmacology, Faculty of Medicine, Trisakti University Correspondence
More informationStudy No: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationAdvances in the Treatment of Migraine
Advances in the Treatment of Migraine C. Philip O Carroll, M.D. Director Neurobehavioral Medicine Hoag Neurosciences Institute Guyuron B Headache, 2015;55:1464-1473 I m sorry your head hurts, sweetie.is
More informationSUMMARY OF PRODUCT CHARACTERISTICS. Zolmitriptan Each 2.5 mg film-coated tablet contains 2.5 mg zolmitriptan
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Zomig TM 2.5 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Zolmitriptan Each 2.5 mg film-coated tablet contains
More informationInpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents
Headache 2008 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2008.01293.x Published by Wiley Periodicals, Inc. Brief Communication Inpatient Treatment
More informationORIGINAL ARTICLE INTRODUCTION
ORIGINAL ARTICLE The Efficacy of Propofol vs. Subcutaneous Sumatriptan for Treatment of Acute Migraine Headaches in the Emergency Department: A Double-Blinded Clinical Trial Hossein Moshtaghion, MD*; Najmeh
More information10/17/2017 CHRONIC MIGRAINES BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES PATIENT CASE EPIDEMIOLOGY EPIDEMIOLOGY
BOTOX: TO INJECT OR NOT INJECT? IN CHRONIC MIGRAINE PROPHYLAXIS OBJECTIVES JENNIFER SHIN, PHARMD PGY2 AMBULATORY CARE PHARMACY RESIDENT COMMUNITYCARE HEALTH CENTERS PHARMACOTHERAPY ROUNDS OCTOBER 20, 2017
More informationCrossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine in Migraine
Original Paper Eur Neurol 2003;49:20 29 DOI: 10.1159/000067018 Received: March 13, 2002 Accepted: September 10, 2002 Crossover Comparison of Efficacy and Preference for Rizatriptan 10 mg versus Ergotamine/Caffeine
More informationFinancial Support: This study was co-funded by OptiNose US, Inc., Yardley, PA, USA, and Avanir Pharmaceuticals, Inc., Aliso Viejo, CA, USA.
Headache 2015 The Authors. Headache: The Journal of Head and Face Pain published by Wiley Periodicals, Inc. on behalf of American Headache Society ISSN 0017-8748 doi: 10.1111/head.12583 Published by Wiley
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 5 Last Review Date: December 2, 2016 Sumatriptan Description Sumatriptan
More informationSalapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup.
Salapin Salbutamol Syrup 2mg/5mL Qualitative and quantitative composition Salapin: Salbutamol BP 2mg as sulphate in each 5mL of a raspberry cola flavoured, sugar free syrup. Clinical particulars Therapeutic
More informationDrug Class Review Triptans
Drug Class Review Triptans Preliminary Update Scan #3 February 2014 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationIdentification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database
doi:10.1111/j.1468-2982.2007.01457.x Identification of negative predictors of pain-free response to triptans: Analysis of the eletriptan database H-C Diener 1, DW Dodick 2, PJ Goadsby 3, RB Lipton 4, M
More informationAdult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationDrug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc.
Drug Name: Aprepitant (Emend ) Manufacturer: Merck & Co., Inc. Pharmacology: Aprepitant (previously known as MK-0839 and L-754030) is a new molecular entity that is the first in a new therapeutic class,
More informationResearch Submission. ISSN doi: /head Published by Wiley Periodicals, Inc.
Headache 213 The Authors Headache published by Wiley Periodicals, Inc. on behalf of American Headache Society ISSN 17-8748 doi: 1.1111/head.12257 Published by Wiley Periodicals, Inc. Research Submission
More informationIs the Migraid device an asset in the non-pharmacologic treatment of migraine?
Acta neurol. belg., 2007, 107, 40-46 Is the Migraid device an asset in the non-pharmacologic treatment of migraine? Herman PIETERSE 1,3, Joop A. M. KUSTER 2 and Luc M. VAN BORTEL 1 1 Heymans Institute
More informationORIGINAL CONTRIBUTION. Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain
ORIGINAL CONTRIBUTION Efficacy and Safety of Acetaminophen, Aspirin, and Caffeine in Alleviating Migraine Headache Pain Three Double-blind, Randomized, -Controlled Trials Richard B. Lipton, MD; Walter
More informationCLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS
CLINICAL INVESTIGATION OF ANTI-ANGINAL MEDICINAL PRODUCTS IN STABLE ANGINA PECTORIS Guideline Title Clinical Investigation of Anti-Anginal Medicinal Products in Stable Angina Pectoris Legislative basis
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
Committed to Transforming the Treatment Paradigm for Migraine Prevention 36th Annual J.P. Morgan Healthcare Conference January 8, 2018 Forward-Looking Statements This presentation and the accompanying
More informationACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli
The European Headache School 2012 ACUTE TREATMENT FOR MIGRAINE Cristina Tassorelli Headache Science Centre, IRCCS Neurological Institute C. Mondino Foundation - Pavia University Centre for Adaptive Disorders
More information